|
1）Cornwell GG 3rd, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983; 75: 618-23
|
|
|
|
2）Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011; 24: 1533-44
|
|
|
|
|
|
3）Fuchs U, Zittermann A, Suhr O, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant. 2005; 5: 1159-62
|
|
|
|
|
|
4）Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79: 785-92
|
|
|
|
|
|
5）Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87: 2843-5
|
|
|
|
|
|
6）Tanskanen M, Kiuru-Enari S, Tienari P, et al. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid. 2006; 13: 164-9
|
|
|
|
|
|
7）Kodaira M, Sekijima Y, Tojo K, et al. Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Journal of the peripheral nervous system: JPNS. 2008; 13: 148-50. Epub 2008/07/08
|
|
|
|
|
|
8）Yamano M, Azuma A, Yazaki M, et al. Early cardiac involvement in senile systemic amyloidosis: a case report. Amyloid. 2008; 15: 54-9
|
|
|
|
|
|
9）Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Int Med. 2005; 165: 1425-9
|
|
|
|
|
|
10）Chung CM, Connors LH, Benson MD, et al. Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis. Amyloid. 2001; 8: 75-83
|
|
|
|
|
|
11）Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006; 47: 1724-5
|
|
|
|
|
|
12）Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013; 52: 1913-26
|
|
|
|
|
|
13）Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998; 91: 141-57
|
|
|
|
|
|
14）Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996; 77: 313-5
|
|
|
|
|
|
15）Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95: 535-7
|
|
|
|
|
|
16）Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98: 1442-8
|
|
|
|
|
|
17）Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129: 1840-9
|
|
|
|
|
|
18）Hongo M, Hirayama J, Fujii T, et al. Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. Am Heart J. 1987; 113: 654-62
|
|
|
|
|
|
19）Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008; 51: 1022-30
|
|
|
|
|
|
20）Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Association. 2013; 2: e000098
|
|
|
|
|
|
21）Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310: 2658-67
|
|
|
|
|
|
22）Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012; 109: 9629-34
|
|
|
|
|
|
23）Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol. 2000; 7: 312-21
|
|
|
|
|
|
24）Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A. 2005; 102: 14545-50
|
|
|
|
|
|
25）Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014; 39: 225-33
|
|
|
|
|